When astronaut Scott Kelly returns to Earth on March 1, half of NASA’s first-of-its-kind study of twin astronauts and long duration space flight, researchers at University of California, San Diego School of Medicine and elsewhere will launch the mission’s next phase.
Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. Researchers at University of California, San Diego School of Medicine have discovered that a protein known as p62 acts as a molecular brake to keep inflammation in check and avoid collateral damage.
Delivering on the late astronaut Sally Ride’s pioneering spirit, UC San Diego today announced the official launch of Sally Ride Science at UC San Diego with a slate of summer workshops in science, technology, engineering, art and math, or STEAM, aimed at young women in middle school and high school.
A new cyber-archaeology research center in the Qualcomm Institute at UC San Diego has received data on 18,500 archaeological sites under a new partnership between the center and the Israel Antiques Authority.
This month’s announcement by the National Science Foundation that scientists for the first time detected gravitational waves in the universe as hypothesized by Albert Einstein 100 years ago has opened up a new era of exploration for astronomers and astrophysicists. The NSF-funded Comet supercomputer at the San Diego Supercomputer Center (SDSC) at the University of California, San Diego, which went into operation in May 2015, was one of several high-performance computers used by researchers to help confirm that landmark discovery before a formal announcement was made.
Cancer immunology is based upon boosting the body’s own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells – one of the immune system’s primary weapons – to treat three different types of blood cancer that often defy existing therapies.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
